New hope for advanced breast cancer: drug combo enters human trials
NCT ID NCT06167694
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs together (HRS-8080 and dalpiciclib) in people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combination can shrink tumors. About 146 women aged 18-75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER-POSITIVE, HER2-NEGATIVE UNRESECTABLE OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital Fifth Medical Center
RECRUITINGBeijing, Beijing Municipality, 100000, China
-
Sun Yat-sen University Cancer Center (SYSUCC)
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.